LAUSR

4. Illumina, Inc. Multiplexing Sample Preparation Guide (Part # 1005361 Rev. D). 2011. 5. Roche NimbleGen, Inc.NimbleGen SeqCap EZ Exome Library SR User’s Guide (Version 2.2). 2010. 6. Bainbridge MN, Wang M, Wu Y, Newsham I, Muzny DM, Jefferies JL, et al. Targeted Enrichment beyond the consensus coding DNA sequence exome reveals exons with higher variant densities. Genome Biol. 2011;12:pp12. 7. Richards CS, Bale S, Bellissimo DB, Das S, Grody WW, Hegde MR, et al., Molecular Subcommittee of the ACMG Laboratory Quality Assurance Committee. ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007. Genet Med. 2008;10: 294—300. 8. Dinwiddie DL, Soden SE, Saunders CJ, Miller NA, Farrow EG, Smith LD, et al. De novo frameshift mutation in ASXL3 in a patient with global developmental delay, microcephaly, and craniofacial anomalies. BMC Med Genomics. 2013;6:6—32. 9. Zhu X, Petrovski S, Xie P, Ruzzo EK, Lu YF, McSweeney KM, et al. Whole-exome sequencing in undiagnosed genetic diseases: Interpreting 119 trios. Genet Med. 2015;17:774—81. 10. Hori I, Miya F, Ohashi K, Negishi Y, Hattori A, Ando N, et al. Novel splicing mutation in the ASXL3 gene causing Bainbridge-Ropers syndrome. Am J Med Genet Part A. 2016;170:1863—7. 11. Srivastava A, Ritesh KC, Tsan YC, Liao R, Su F, Cao X, et al. De novo dominant ASXL3 mutations alter H2A deubiquitination and transcription in Bainbridge-Ropers syndrome. Hum Mol Genet. 2016;25:597—608. 12. Hastings R, Cobben JM, Gillessen-Kaesbach G, Goodship J, Hove H, Kjaergaard S, et al. Bohring-Opitz (Oberklaid-Danks) syndrome: clinical study, review of the literature, and discussion of possible pathogenesis. EUR J Hum Genet. 2011;19: 513—9. 13. Hoischen A, van Bon Bregje WM, Rodríguez-Santiago B, Gilissen C, Vissers LEL, de Vries P, et al. De novo nonsense mutations in ASXL1 cause Bohring-Opitz syndrome. Nat Genet. 2011;43:729—31.